share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Patel Naimish

CRISPR Therapeutics | 4：持股变动声明-高管 Patel Naimish
美股SEC公告 ·  05/29 16:20
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG's Chief Medical Officer, Patel Naimish, was involved in a transaction with the company's stock on May 28, 2024. However, the details of the transaction, including the action type, status, number of shares, nature of shares, transaction price, and total value of shares, have not been disclosed. The number of shares held by Patel Naimish after the transaction is also undisclosed. Investors are advised to await further information for a complete understanding of the transaction's impact on their investment decisions.
CRISPR Therapeutics AG's Chief Medical Officer, Patel Naimish, was involved in a transaction with the company's stock on May 28, 2024. However, the details of the transaction, including the action type, status, number of shares, nature of shares, transaction price, and total value of shares, have not been disclosed. The number of shares held by Patel Naimish after the transaction is also undisclosed. Investors are advised to await further information for a complete understanding of the transaction's impact on their investment decisions.
2024年5月28日，CRISPR Therapeutics AG的首席医疗官帕特尔·奈米什参与了与该公司股票的交易。但是，该交易的细节，包括行动类型、状态、股票数量、股票性质、交易价格和股票总价值，尚未披露。交易后帕特尔·奈米什持有的股票数量也未公开。建议投资者等待进一步的信息，以全面了解该交易对其投资决策的影响。
2024年5月28日，CRISPR Therapeutics AG的首席医疗官帕特尔·奈米什参与了与该公司股票的交易。但是，该交易的细节，包括行动类型、状态、股票数量、股票性质、交易价格和股票总价值，尚未披露。交易后帕特尔·奈米什持有的股票数量也未公开。建议投资者等待进一步的信息，以全面了解该交易对其投资决策的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息